0
0
The Central Drugs Standard Control Organization (CDSCO) has released new draft guidelines governing the regulation of medical device software in India, marking a major step toward harmonizing domestic rules with international standards. Announced by the Drugs Controller General of India (DCGI) this week, the 76-page draft—open for public comment over the next 30 days—sets out detailed requirements for the licensing, quality management, and performance evaluation of Software as a Medical Device (SaMD) and Software in a Medical Device (SiMD).
Key Developments and Context
The updated Guidance Document on Medical Device Software aims to clarify technical definitions, classification systems, and compliance expectations for medical software manufacturers and importers. It introduces standardized processes for clinical investigations and performance evaluations, including those relevant to in vitro diagnostics (IVDs). The move comes in response to rapid growth in digital health technologies and the increasing incorporation of artificial intelligence (AI) and machine learning (ML) into medical devices, creating regulatory complexities.
India’s Medical Devices Rules (2017) already permit the use of international standards for assessing safety and performance. However, the latest draft expands on key concepts—such as validation protocols, algorithm risk assessments, and post-market surveillance—bringing India closer to the frameworks adopted by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Industry Calls for Greater Clarity
While the draft has been widely welcomed, the Medical Technology Association of India (MTaI)—representing multinational device makers—has urged the regulator to clarify evaluation protocols for emerging AI/ML-based devices. In a statement, the group noted that “the final document should provide greater clarity on clinical evaluation protocols and algorithm change management, particularly for AI/ML-based medical devices.”
Pavan Choudary, Chairman of MTaI, called the guidance a “positive step reflecting CDSCO’s commitment to safe and globally competitive innovation.” However, he emphasized the need for “streamlined compliance for low-risk SaMDs to ensure regulatory proportionality.” This highlights a growing concern among manufacturers about balancing oversight with innovation potential, especially as adaptive algorithms evolve continuously and may require dynamic regulatory review.
Expert Perspectives
According to Dr. Ananya Verma, a biomedical regulatory affairs expert at the Indian Institute of Public Health, “AI-driven medical devices demand a fundamentally different regulatory mindset. Unlike static devices, their performance can shift with data exposure, meaning regulators must track both algorithm integrity and learning patterns.”
Independent experts argue that while the guidance provides a strong foundation, operational clarity—particularly around algorithm retraining, cybersecurity, and data transparency—will be crucial for ensuring patient safety and fostering manufacturer confidence.
“India’s move to consult stakeholders marks progress toward a more inclusive regulatory ecosystem,” said Dr. Rajesh Jain, a digital health policy advisor. “Yet, it’s vital that the CDSCO integrates real-world evidence and continuous learning mechanisms into oversight frameworks to avoid stifling innovation.”
International and Public Health Implications
The updated guidance could strengthen India’s position as a global MedTech innovation hub, aligning its regulatory environment with international best practices. By addressing safety and interoperability, it may also enhance market access for locally developed digital health technologies.
From a public health standpoint, clearer regulation of AI and software-based devices could build trust among healthcare professionals and patients, ensuring new technologies meet rigorous performance standards. According to the World Health Organization, effective digital health governance can improve risk management and accountability while accelerating innovation in disease detection, remote monitoring, and patient management.
However, experts caution that excessively complex compliance demands may slow adoption, particularly among startups. Simplified protocols for low-risk applications—such as wellness-monitoring apps—could support faster innovation without compromising safety.
Challenges and Next Steps
Despite the guidance’s comprehensive framework, certain issues remain open. Stakeholders have requested detailed guidance on algorithm change protocols—defining when a model update constitutes a “major modification” requiring fresh certification. There are also calls for additional resources within CDSCO to manage the anticipated rise in digital health product submissions.
The public consultation process is expected to invite feedback from software developers, clinicians, and regulatory professionals, potentially resulting in revisions before the final version is formalized later this year. Once enacted, India would join a growing list of nations—such as the United States, Canada, and Singapore—that have adopted specialized frameworks for managing software-based medical technologies.
Implications for Consumers and Developers
For developers, the draft guidance underscores the importance of transparent documentation, robust risk assessments, and alignment with ISO and IEC standards for software development and lifecycle management. For health-conscious consumers and clinicians, it signals emerging regulatory rigor toward digital health solutions increasingly used for diagnostics, chronic disease management, and therapy support.
Patients using app-based platforms or AI-powered diagnostic tools can expect greater accountability from manufacturers as devices undergo standardized evaluations for safety and reliability. Experts recommend consumers continue to verify whether their digital health tools are registered and certified under CDSCO once the updated framework is finalized.
Conclusion
India’s revised framework for medical device software marks a pivotal moment in the evolution of its digital health ecosystem. The guidance’s success will depend on how effectively regulators, industry players, and clinical experts collaborate to reconcile safety oversight with innovation agility. If thoughtfully implemented, it could not only enhance patient protection but also democratize access to safe, intelligent health technologies across India.
Medical Disclaimer:
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
-
Central Drugs Standard Control Organization (CDSCO). “Draft Guidance Document on Medical Device Software,” 2025.
- https://health.economictimes.indiatimes.com/news/medical-devices/cdsco-issues-updated-guidance-on-medical-device-software-lobby-calls-for-clarity-on-ai-ml-device-evaluation-protocols/124737287?utm_source=top_story&utm_medium=homepage
